Chetasi Talati

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman et al. · Journal of Clinical Oncology · 2024 · 184 citations · Full text

Medicine, Oncology, Pharmacology +12

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Andrew Kuykendall, Savan Shah, Chetasi Talati et al. · Annals of Hematology · 2017 · 129 citations

Medicine, Hematology, Pharmacotherapy +8

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia

Onyee Chan, Chetasi Talati, Leidy Isenalumhe et al. · Blood Advances · 2020 · 110 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival

Pragatheeshwar Thirunavukarasu, Chetasi Talati, Sumeet Munjal et al. · JAMA Surgery · 2015 · 108 citations

Medicine, Oncology, Pathology +17

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun et al. · Blood Advances · 2021 · 74 citations · Full text

Medicine, Molecular Genetics, Molecular Medicine +16